Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.